comscoreLonger Time to Chemotherapy Linked to Worse Outcomes in Triple-Negative Disease

Longer Time to Chemotherapy Linked to Worse Outcomes in Triple-Negative Disease

Zaidi Morante, MD explains her research on the timing of chemotherapy in women diagnosed with early-stage triple-negative breast cancer.
Dec 17, 2018
00:00
Download
00:00

Dr. Zaida Morante explains her research that found delaying chemotherapy for more than 30 days was associated with worse outcomes in women diagnosed with early-stage, triple-negative breast cancer. Triple-negative breast cancer is breast cancer that is estrogen-receptor-negative, progesterone-receptor-negative, and HER2-negative.

Listen to the podcast to hear Dr. Morante explain:

  • the design of the study

  • which outcomes delaying chemotherapy affected

  • possible explanations for why chemotherapy was delayed for some women

About the guest
 
morante zaida mug
Zaida Morante, MD

Dr. Zaida Morante is a medical oncologist at Instituto Nacional de Enfermedades Neoplásicas in Lima, Peru.

— Last updated on June 29, 2022, 2:49 PM

 
Lilly

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate